| abstract |
The present invention provides a pharmaceutical composition comprising human immature dental pulp stem cells (hIDPSC), wherein the hIDPSC expresses CD44 and CD13. The invention also provides a method of treating a neurological disease or condition comprising systemic administration of a pharmaceutical composition comprising hIDPSC to a subject, wherein hIDPSC expresses CD44 and CD13. For example, for treatment of a neurological disease or condition, including supporting a neuroprotective mechanism in a subject diagnosed with primary HD, or repairing lost DA neurons in a subject diagnosed with PD. 【Selection chart】 None |